Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Return on Capital Employed (2022 - 2026)

Zentalis Pharmaceuticals has reported Return on Capital Employed over the past 5 years, most recently at 61.51% for Q1 2026.

  • For Q1 2026, Return on Capital Employed fell 224.0% year-over-year to 61.51%; the TTM value through Mar 2026 reached 61.51%, down 224.0%, while the annual FY2025 figure was 47.3%, 367.0% down from the prior year.
  • Return on Capital Employed for Q1 2026 was 61.51% at Zentalis Pharmaceuticals, down from 56.27% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 47.59% in Q4 2022 and troughed at 61.51% in Q1 2026.
  • A 5-year average of 53.74% and a median of 53.29% in 2023 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: plummeted -1239bps in 2023 and later surged 1068bps in 2024.
  • Year by year, Return on Capital Employed stood at 47.59% in 2022, then fell by -26bps to 59.98% in 2023, then rose by 18bps to 49.31% in 2024, then dropped by -14bps to 56.27% in 2025, then fell by -9bps to 61.51% in 2026.
  • Business Quant data shows Return on Capital Employed for ZNTL at 61.51% in Q1 2026, 56.27% in Q4 2025, and 54.67% in Q3 2025.